Skip to main content

Defect of Articular Cartilage

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AbelZeta Pharma
AbelZeta PharmaChina - Shanghai
1 program
1
ReJoinTMPhase 21 trial
Active Trials
NCT02855073Unknown28Est. Dec 2019
Arthrex
ArthrexCA - Santa Barbara
1 program
Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the KneeN/A1 trial
Active Trials
NCT02203071Completed25Est. Sep 2018
Anika Therapeutics
Anika TherapeuticsMA - Bedford
1 program
HyalofastN/A1 trial
Active Trials
NCT02659215Active Not Recruiting200Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbelZeta PharmaReJoinTM
Anika TherapeuticsHyalofast
ArthrexComparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee

Clinical Trials (3)

Total enrollment: 253 patients across 3 trials

Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects

Start: Jul 2014Est. completion: Dec 201928 patients
Phase 2Unknown

HyaloFAST Trial for Repair of Articular Cartilage in the Knee

Start: Dec 2015Est. completion: Jun 2026200 patients
N/AActive Not Recruiting
NCT02203071ArthrexComparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee

Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee

Start: Jun 2014Est. completion: Sep 201825 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.